A Phase 1, Multicenter, Open-label, Dose-Escalation Trial to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia
Phase of Trial: Phase I
Latest Information Update: 17 Feb 2017
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Otsuka Pharmaceutical
- 07 Jun 2017 Biomarkers information updated
- 14 Feb 2017 Status changed from recruiting to completed.
- 08 Dec 2016 Planned End Date changed from 1 Sep 2016 to 1 Jan 2017.